PMID- 27835987
OWN - NLM
STAT- MEDLINE
DCOM- 20170929
LR  - 20211204
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 16
IP  - 1
DP  - 2016 Nov 11
TI  - Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR 
      expression in patients with esophageal squamous cell carcinoma: a systematic 
      review and meta-analysis.
PG  - 877
LID - 877
AB  - BACKGROUND: Mammalian target of rapamycin (mTOR) is a serine/threonine protein 
      kinase responsible for regulating ribosomal biogenesis and protein synthesis. 
      Dysregulation of mTOR contributes to tumorigenesis, angiogenesis, cellular growth 
      and metastasis but its roles in esophageal squamous cell carcinoma (ESCC) are 
      controversial. Therefore, the objective of this study is to evaluate the 
      prognostic and clinicopathological significance of mTOR/p-mTOR expression in 
      ESCC. METHODS: Literature retrieval was conducted by searching PubMed, EMBASE and 
      the Web of Science for full-text papers that met our eligibility criteria. Odds 
      ratio (OR) and hazard ratio (HR) with 95 % confidence interval (CI) served as the 
      appropriate summarized statistics for assessments of clinicopathological and 
      prognostic significance, respectively. Cochrane Q-test and I(2)-statistic were 
      adopted to estimate the heterogeneity level between studies. Potential 
      publication bias was detected by Begg's test and Egger's test. RESULTS: A total 
      of 915 ESCC patients from nine original articles were included into this 
      meta-analysis. The pooled analyses suggested that mTOR/p-mTOR expression was 
      significantly correlated with the unfavorable outcomes of differentiation degree 
      (OR: 2.63; 95 % CI: 1.71-4.05; P = 0.001), tumor invasion (OR: 1.48; 95 % CI: 
      1.02-2.13; P = 0.037), TNM stage (OR: 2.25; 95 % CI: 1.05-4.82; P = 0.037) and 
      lymph node metastasis (OR: 1.82; 95 % CI: 1.06-3.11; P = 0.029), but had no 
      significant relationship to the genders (OR: 0.81; 95 % CI: 0.50-1.32; 
      P = 0.396). Moreover, mTOR/p-mTOR expression could independently predict the 
      worse overall survival (HR: 2.04; 95 % CI: 1.58-2.62; P < 0.001), disease-free 
      survival (HR: 2.39; 95 % CI: 1.64-3.49; P < 0.001) and cancer-specific survival 
      (HR: 1.62; 95 % CI: 1.18-2.23; P = 0.003) of patients with ESCC. Such prognostic 
      value of mTOR was not substantially altered by further subgroup analyses. 
      CONCLUSIONS: Positive expression of mTOR and p-mTOR was significantly associated 
      with the unfavorable conditions on the depth of tumor invasion, TNM stage, 
      differentiation degree and lymph node metastasis. mTOR and p-mTOR could serve as 
      a valuable predictor for the poor prognosis of ESCC. More high-quality worldwide 
      studies performing a multivariate analysis based on larger sample size are 
      urgently required for further verifying and modifying our findings in the future.
FAU - Li, Shuangjiang
AU  - Li S
AD  - Department of Thoracic Surgery, West China Hospital, Sichuan University, Guoxue 
      Alley No. 37, Chengdu, China.
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, Guoxue Alley No. 37, Chengdu, China.
FAU - Wang, Zhiqiang
AU  - Wang Z
AD  - Department of Thoracic Surgery, West China Hospital, Sichuan University, Guoxue 
      Alley No. 37, Chengdu, China.
FAU - Huang, Jian
AU  - Huang J
AD  - Department of Thoracic Surgery, West China Hospital, Sichuan University, Guoxue 
      Alley No. 37, Chengdu, China.
FAU - Cheng, Shan
AU  - Cheng S
AD  - Department of Sonography, West China Hospital, Sichuan University, Guoxue Alley 
      No. 37, Chengdu, China.
FAU - Du, Heng
AU  - Du H
AD  - Department of Thoracic Surgery, West China Hospital, Sichuan University, Guoxue 
      Alley No. 37, Chengdu, China.
FAU - Che, Guowei
AU  - Che G
AD  - Department of Thoracic Surgery, West China Hospital, Sichuan University, Guoxue 
      Alley No. 37, Chengdu, China. guowei_che@foxmail.com.
FAU - Peng, Yong
AU  - Peng Y
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, Guoxue Alley No. 37, Chengdu, China. yongpeng@scu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20161111
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Phosphoproteins)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Squamous Cell/*enzymology/mortality/secondary
MH  - Esophageal Neoplasms/*enzymology/mortality/pathology
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Neoplasm Invasiveness
MH  - Phosphoproteins/metabolism
MH  - Phosphorylation
MH  - Prognosis
MH  - Protein Processing, Post-Translational
MH  - Survival Analysis
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC5106813
OTO - NOTNLM
OT  - Esophageal squamous cell carcinoma
OT  - Mammalian target of rapamycin (mTOR)
OT  - Meta-analysis
OT  - Prognosis
OT  - Systematic review
EDAT- 2016/11/12 06:00
MHDA- 2017/09/30 06:00
PMCR- 2016/11/11
CRDT- 2016/11/13 06:00
PHST- 2016/08/02 00:00 [received]
PHST- 2016/10/28 00:00 [accepted]
PHST- 2016/11/13 06:00 [entrez]
PHST- 2016/11/12 06:00 [pubmed]
PHST- 2017/09/30 06:00 [medline]
PHST- 2016/11/11 00:00 [pmc-release]
AID - 10.1186/s12885-016-2940-7 [pii]
AID - 2940 [pii]
AID - 10.1186/s12885-016-2940-7 [doi]
PST - epublish
SO  - BMC Cancer. 2016 Nov 11;16(1):877. doi: 10.1186/s12885-016-2940-7.